NAD

NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE

 Coordinatore UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA 

 Organization address address: PIAZZA DELL'ATENEO NUOVO 1
city: MILANO
postcode: IT-20126

contact info
Titolo: Ms.
Nome: Fiorenza
Cognome: Coviello
Email: send email
Telefono: -264488268
Fax: -264488029

 Nazionalità Coordinatore Italy [IT]
 Sito del progetto http://www.nadproject.eu/
 Totale costo 14˙365˙090 €
 EC contributo 10˙921˙350 €
 Programma FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies
 Code Call FP7-NMP-2007-LARGE-1
 Funding Scheme CP-IP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-09-01   -   2013-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

 Organization address address: PIAZZA DELL'ATENEO NUOVO 1
city: MILANO
postcode: IT-20126

contact info
Titolo: Ms.
Nome: Fiorenza
Cognome: Coviello
Email: send email
Telefono: -264488268
Fax: -264488029

IT (MILANO) coordinator 0.00
2    "STAB VIDA, INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA."

 Organization address address: RUA DOS INVENTORES SN EDIFICIO MADAN SETUBAL CONCELHO ALMADA FREGUESIA CAPARICA E TRAFARIA
city: OEIRAS
postcode: 2825 182

contact info
Titolo: Ms.
Nome: Carla
Cognome: Clemente
Email: send email
Telefono: +351 214469765
Fax: +351 214469740

PT (OEIRAS) participant 0.00
3    Academisch Medisch Centrum bij de Universiteit van Amsterdam

 Organization address address: MEIBERGDREEF 9
city: AMSTERDAM
postcode: 1105AZ

contact info
Titolo: Ms.
Nome: Marinella
Cognome: Vermaas
Email: send email
Telefono: 00-31-20-5665558
Fax: 00-31-20-6915462

NL (AMSTERDAM) participant 0.00
4    BIAL INDUSTRIAL FARMACEUTICA S.A.

 Organization address address: Alameda Urquijo
city: BILBAO
postcode: 48008

contact info
Titolo: Dr.
Nome: Alberto
Cognome: Martinez
Email: send email
Telefono: +34 944438000
Fax: +34 944438016

ES (BILBAO) participant 0.00
5    BIOTALENTUM TUDASFEJLESZTO KFT

 Organization address address: AULICH LAJOS UTCA 26
city: GOEDOELLO
postcode: 2100

contact info
Nome: Zsuzsanna
Cognome: Héricsné Buda
Email: send email
Telefono: -727
Fax: 36 28 526 243

HU (GOEDOELLO) participant 0.00
6    CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS

 Organization address address: "Hospital Universitario ""Virgen del Rocio"" - Edif. de Laboratorios, 2a planta - Avda. Manual Siurot S/N"
city: SEVILLA
postcode: 41013

contact info
Titolo: Dr.
Nome: Michael
Cognome: Patterson
Email: send email
Telefono: 34-95 5012648
Fax: 34- 91 1964420

ES (SEVILLA) participant 0.00
7    CHEMICKY USTAV SLOVENSKEJ AKADEMIEVIED

 Organization address address: DUBRAVSKA CESTA 9
city: BRATISLAVA
postcode: 845

contact info
Titolo: Dr.
Nome: Igor
Cognome: Tvaroška
Email: send email
Telefono: +421 2 54772080
Fax: +421 2 59410222

SK (BRATISLAVA) participant 0.00
8    GUERBET SA

 Organization address address: RUE DES VANESSES 15
city: VILLEPINTE
postcode: 93420

contact info
Titolo: Mr.
Nome: Jean-François
Cognome: Morin
Email: send email
Telefono: +33 1 45 91 50 18
Fax: +33 1 45 91 51 23

FR (VILLEPINTE) participant 0.00
9    ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

 Organization address address: Via Giuseppe La Masa 19
city: MILANO
postcode: 20156

contact info
Titolo: Dr.
Nome: Mario
Cognome: Salmona
Email: send email
Telefono: +39-02.39014.447
Fax: +39-02.39014.744

IT (MILANO) participant 0.00
10    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Mr.
Nome: Edin
Cognome: Ulf
Email: send email
Telefono: 46-8-585-876-04
Fax: -

SE (STOCKHOLM) participant 0.00
11 KOBENHAVNS UNIVERSITET DK participant 0.00
12    LANCASTER UNIVERSITY

 Organization address address: BAILRIGG
city: LANCASTER
postcode: LA1 4YW

contact info
Titolo: Prof.
Nome: David
Cognome: Allsop
Email: send email
Telefono: 44-1524-592122
Fax: 44-1524-593192

UK (LANCASTER) participant 0.00
13    NANOVECTOR SRL

 Organization address address: VIA LIVORNO 60
city: TORINO
postcode: 10144

contact info
Titolo: Dr.
Nome: Paolo
Cognome: Gasco
Email: send email
Telefono: 390112000000
Fax: 390112000000

IT (TORINO) participant 0.00
14    TURUN YLIOPISTO

 Organization address address: YLIOPISTONMAKI
city: TURUN YLIOPISTO
postcode: 20014

contact info
Titolo: Dr.
Nome: Eliisa
Cognome: Särkilahti
Email: send email
Telefono: -3335799
Fax: -3336090

FI (TURUN YLIOPISTO) participant 0.00
15    UNIVERSIDAD DEL PAIS VASCO/ EUSKAL HERRIKO UNIBERTSITATEA

 Organization address address: BARRIO SARRIENA S N
city: LEIOA
postcode: 48940

contact info
Titolo: Prof.
Nome: Félix M.
Cognome: Goni
Email: send email
Telefono: 34946012625
Fax: 34946013360

ES (LEIOA) participant 0.00
16    UNIVERSITE PARIS-SUD

 Organization address address: RUE GEORGES CLEMENCEAU 15
city: ORSAY
postcode: 91405

contact info
Titolo: Ms.
Nome: Michèle
Cognome: Hamon
Email: send email
Telefono: +33 (0) 1 69 15 70 46
Fax: +33 (0) 1 69 15 55 99

FR (ORSAY) participant 0.00
17    UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6

 Organization address address: Place Jussieu 4
city: PARIS
postcode: 75252

contact info
Titolo: Mr.
Nome: Thomas
Cognome: Wiest
Email: send email
Telefono: +33 1 44 27 87 58
Fax: +33 1 44 27 74 67

FR (PARIS) participant 0.00
18    UNIVERSITEIT ANTWERPEN

 Organization address address: PRINSSTRAAT 13
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Prof.
Nome: Annemie
Cognome: Van Der Linden
Email: send email
Telefono: -2653201
Fax: -2653204

BE (ANTWERPEN) participant 0.00
19    UNIVERSITY OF PATRAS

 Organization address address: UNIVERSITY CAMPUS RIO PATRAS
city: RIO PATRAS
postcode: 26500

contact info
Titolo: Dr.
Nome: Sophia
Cognome: Antimisiaris
Email: send email
Telefono: 0030-2610-969332
Fax: 0030-2610-996302

EL (RIO PATRAS) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

molecules    lipid    solid    oral    disaggregate    imaging    central    models    treatment    demonstrated    peptide    bbb    crossing    form    nanoparticles    sink    barrier    alzheimer    functionalised    brain    animal    therapy    polymeric    excess    blood    disease    million    amyloid    international    diagnosis    remove    drugs    dementia    contrast    nad    nps    nasal    ad    combined    dramatically    effect    liposomes    beta    deposits   

 Obiettivo del progetto (Objective)

'The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular plaques mainly composed of Aβ are a hallmark of post-mortem brains. These premises strongly suggest brain Aβ as a possible target for therapy and diagnosis of AD. In addition, it is known that brain and blood Aβ pools are in equilibrium via the blood-brain-barrier (BBB). Accordingly, it has been reported that removal of blood Aβ may withdraw the excess of brain Aβ by a “sink” effect. Thus, blood Aβ is another potential target. The aim of this project is to utilize nanoparticles (NPs) specifically engineered for targeting brain Aβ, for the combined diagnosis and therapy (theranostics) of AD. NPs (liposomes, solid lipid NPs, polymeric-NPs) will be multiple-functionalized with: i) a large arsenal of molecules (specific lipids, antiamyloidogenic drugs, polyphenols, heteroaromatic compounds, unnatural peptides and peptidomimetics, antibodies) interacting with Aβ in all aggregation forms, ii) PET or MRI contrast agents detecting such interaction, iii) molecules stimulating BBB crossing via the transcytotic route. Several artificial and cellular models will be used to fine-tune such features and to improve NPs biocompatibility, non-immunogenicity, non-toxicity and physical stability. Eventually, absorption, distribution, metabolism and excretion will be studied using animal models of AD. Different routes (i.v., oral, nasal) and protocols (two-step, NPs cocktails, aerosols) of administration will be utilized to boost NPs brain delivery. The prediction is that NPs will detect, disaggregate and remove Aβ brain deposits. In any case, NPs will interact with blood Aβ, withdrawing the excess of brain peptide by a “sink” effect.'

Introduzione (Teaser)

Tiny warriors fight Alzheimer's

Descrizione progetto (Article)

Dementia affects more than 24 million people globally with one new case diagnosed every seven seconds. Three million of the 5 million cases in Europe are classified as AD, the most common form of dementia. As the aging population continues to grow, the numbers are expected to rise dramatically.

Amyloid deposits in the brain are characteristic of AD but treatment is ironically complicated by the protective-in-function blood - brain barrier. This barrier has prevented the use of simple oral or nasal interventions to deliver drugs through the blood to the targeted area in the brain.

EU-funded scientists working on the project 'Nanoparticles for therapy and diagnosis of Alzheimer Disease' (http://www.nadproject.eu (NAD)) exploited nanoparticles to do the job. Their very small size imparts powerful functionalities to nanoparticles such as enhanced contrast during imaging procedures and crossing the blood - brain barrier. NAD functionalised a variety of nanoparticles including liposomes, solid lipid nanoparticles and polymeric nanoparticles.

Through positron emission tomography and magnetic resonance imaging, researchers' demonstrated that these nanoparticles could disaggregate and remove amyloid deposits, restoring impaired memory in animal models. The amazing success of the multi-functionalised nanoparticles of various types has been recognised internationally.

The project won second place in the 'Best Completed Project Contest' with the award presented by the Director responsible for Research and Innovation in the European Commission. Outcomes resulted in more than 50 publications in international peer-reviewed scientific journals and four international patent applications.

Demonstrated combined diagnosis and therapy of AD with orally or nasally administered nanoparticles is an exceptional advance in the war against a devastating disease. This technique opens the door for treatment of other central nervous system disorders through nanoparticle-based diagnostics for an even broader spectrum of diseases. This will enhance the quality of life for millions of patients and their families through better health while dramatically increasing EU industrial competitiveness.

Altri progetti dello stesso programma (FP7-NMP)

EMC2-FACTORY (2011)

Eco Manufactured transportation means from Clean and Competitive Factory

Read More  

FASHION-ABLE (2011)

"Development of new technologies for the flexible and eco-efficient production of customized healthy clothing, footwear and orthotics for consumers with highly individualised needs"

Read More  

PHOENIX (2013)

Synergic combination of high performance flame retardant based on nano-layered hybrid particles as real alternative to halogen based flame retardant additives

Read More